Compare · HELP vs NVO
HELP vs NVO
Side-by-side comparison of Cybin Inc. (HELP) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HELP and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 215.1x HELP ($807.3M).
- HELP has been more active in the news (19 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 3 for HELP).
- Company
- Cybin Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $807.3M
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 19
- 4
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HELP
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma Appoints Dr. Suresh Durgam to Board of Directors
- SEC Form 6-K filed by Cybin Inc.
- Helus Pharma to Host Investor Presentation on October 21, 2026
- SEC Form 6-K filed by Cybin Inc.
- SEC Form 6-K filed by Cybin Inc.
- Director So Eric H. L. was granted 248,000 shares, increasing direct ownership by 6% to 4,713,014 units (SEC Form 4)
- Chief Financial Officer Cavers Greg bought $38,730 worth of shares (3,000 units at $12.91) (SEC Form 4)
- New insider Cavers Greg claimed ownership of 125,937 shares (SEC Form 3)
- Chief Growth Officer Glavine Paul was granted 248,000 shares, increasing direct ownership by 6% to 4,750,191 units (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank